233 related articles for article (PubMed ID: 25805926)
1. Novel CD9-targeted therapies in gastric cancer.
Murayama Y; Oritani K; Tsutsui S
World J Gastroenterol; 2015 Mar; 21(11):3206-13. PubMed ID: 25805926
[TBL] [Abstract][Full Text] [Related]
2. CD9 expression in gastric cancer and its significance.
Hori H; Yano S; Koufuji K; Takeda J; Shirouzu K
J Surg Res; 2004 Apr; 117(2):208-15. PubMed ID: 15047125
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.
Nakamoto T; Murayama Y; Oritani K; Boucheix C; Rubinstein E; Nishida M; Katsube F; Watabe K; Kiso S; Tsutsui S; Tamura S; Shinomura Y; Hayashi N
J Gastroenterol; 2009; 44(9):889-96. PubMed ID: 19468669
[TBL] [Abstract][Full Text] [Related]
4. Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells.
Rappa G; Green TM; Karbanová J; Corbeil D; Lorico A
Oncotarget; 2015 Apr; 6(10):7970-91. PubMed ID: 25762645
[TBL] [Abstract][Full Text] [Related]
5. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells.
Ovalle S; Gutiérrez-López MD; Olmo N; Turnay J; Lizarbe MA; Majano P; Molina-Jiménez F; López-Cabrera M; Yáñez-Mó M; Sánchez-Madrid F; Cabañas C
Int J Cancer; 2007 Nov; 121(10):2140-52. PubMed ID: 17582603
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
Yashiro M; Matsuoka T
World J Gastroenterol; 2016 Feb; 22(8):2415-23. PubMed ID: 26937130
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy.
Soyuer S; Soyuer I; Unal D; Ucar K; Yildiz OG; Orhan O
Pathol Res Pract; 2010 Sep; 206(9):607-10. PubMed ID: 20547009
[TBL] [Abstract][Full Text] [Related]
8. [Tetraspanins: a new target for antiangiogenic therapy?].
Vasse M; Colin S; Guilmain W; Creoff E; Muraine M; Vannier JP; Al-Mahmood S
Ann Pharm Fr; 2015 Mar; 73(2):100-7. PubMed ID: 25745942
[TBL] [Abstract][Full Text] [Related]
9. Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways.
Noda N; Matsumoto K; Fukuyama S; Asai Y; Kitajima H; Seki N; Matsunaga Y; Kan-O K; Moriwaki A; Morimoto K; Inoue H; Nakanishi Y
Int Immunol; 2013 Nov; 25(11):643-50. PubMed ID: 23988617
[TBL] [Abstract][Full Text] [Related]
10. Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner.
Copeland BT; Bowman MJ; Boucheix C; Ashman LK
Int J Cancer; 2013 Oct; 133(8):1803-12. PubMed ID: 23575960
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for gastric adenocarcinoma.
Almhanna K
Adv Pharmacol; 2012; 65():437-70. PubMed ID: 22959034
[TBL] [Abstract][Full Text] [Related]
12. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity.
Herr MJ; Longhurst CM; Baker B; Homayouni R; Speich HE; Kotha J; Jennings LK
Biochem Biophys Res Commun; 2014 May; 447(4):616-20. PubMed ID: 24747564
[TBL] [Abstract][Full Text] [Related]
13. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells.
Murayama Y; Shinomura Y; Oritani K; Miyagawa J; Yoshida H; Nishida M; Katsube F; Shiraga M; Miyazaki T; Nakamoto T; Tsutsui S; Tamura S; Higashiyama S; Shimomura I; Hayashi N
J Cell Physiol; 2008 Jul; 216(1):135-43. PubMed ID: 18247373
[TBL] [Abstract][Full Text] [Related]
14. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells.
Saito Y; Tachibana I; Takeda Y; Yamane H; He P; Suzuki M; Minami S; Kijima T; Yoshida M; Kumagai T; Osaki T; Kawase I
Cancer Res; 2006 Oct; 66(19):9557-65. PubMed ID: 17018612
[TBL] [Abstract][Full Text] [Related]
15. Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells.
Castro-Sanchez L; Soto-Guzman A; Navarro-Tito N; Martinez-Orozco R; Salazar EP
Eur J Cell Biol; 2010 Nov; 89(11):843-52. PubMed ID: 20709424
[TBL] [Abstract][Full Text] [Related]
16. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
Chen DH; Yu JW; Jiang BJ
World J Gastroenterol; 2015 Sep; 21(33):9707-16. PubMed ID: 26361417
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance.
Kwon HJ; Min SY; Park MJ; Lee C; Park JH; Chae JY; Moon KC
Pathol Res Pract; 2014 May; 210(5):285-90. PubMed ID: 24553302
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
Hong L; Han Y; Liu J; Brain L
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy.
Kamisasanuki T; Tokushige S; Terasaki H; Khai NC; Wang Y; Sakamoto T; Kosai K
Biochem Biophys Res Commun; 2011 Sep; 413(1):128-35. PubMed ID: 21875571
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in the treatment of gastric cancer.
Ngeow J; Tan IB; Choo SP
Asia Pac J Clin Oncol; 2011 Sep; 7(3):224-35. PubMed ID: 21884434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
